Skip to main content
Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
8.60
-0.06 (-0.69%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Karyopharm Therapeutics Revenue

In the year 2025, Karyopharm Therapeutics had annual revenue of $146.07M with 0.57% growth. Karyopharm Therapeutics had revenue of $34.08M in the quarter ending December 31, 2025, with 11.58% growth.

Revenue (ttm)
$146.07M
Revenue Growth
+0.57%
P/S Ratio
1.33
Revenue / Employee
$640,645
Employees
228
Market Cap
193.87M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025146.07M830.00K0.57%
Dec 31, 2024145.24M-796.00K-0.55%
Dec 31, 2023146.03M-11.04M-7.03%
Dec 31, 2022157.07M-52.75M-25.14%
Dec 31, 2021209.82M101.73M94.12%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
MacroGenics 149.50M
OmniAb 18.67M
Caribou Biosciences 11.16M
Whitehawk Therapeutics 7.15M
Korro Bio 6.39M
Cartesian Therapeutics 2.80M
Revenue Rankings

KPTI News

More News